Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Licenses Aficamten Rights in Japan to Bayer for €50 Million Upfront

Positive Impact 4 of 5 product/contract Written later

Cytokinetics granted Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan under an agreement signed November 18, 2024. Cytokinetics will receive a €50 million upfront payment, with additional milestone and royalty payments possible, while it keeps the right to run certain clinical trials in Japan.

Key points

  • Upfront payment of €50 million from Bayer
  • Milestone payments of up to €90 million tied to clinical and launch events in hypertrophic cardiomyopathy
  • Commercial milestones of up to €490 million plus tiered royalties on Japan net sales, from the high teens to the low thirties percent
  • Agreement dated November 18, 2024; full text to be filed with the 2024 Form 10-K

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECNov 19, 2024, 6:02 AM ET
Accession number0000950170-24-128266

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 19, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.